

**SPATA31A1 siRNA**

Catalogue No.: abx934847

siRNA to inhibit SPATA31A1 expression using RNA interference.

This product is provided as two 5 nmol vials (10 nmol), three 5 nmol vials (15 nmol) or 2x three 5 nmol vials (30 nmol) of lyophilized siRNA oligo duplexes. Each vial contains slightly different sequences to ensure full knockout of the gene. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. The siRNA oligos are also chemically modified (2'-OMe) for increased stability and enhanced knockdown in vitro and in vivo.

**Target:** SPATA31A1**Reactivity:** Human**Host:** Synthetic**Tested Applications:** RNAi**Purity:** > 97%**Form:** Lyophilized**Specificity:** SPATA31A1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.**Storage:** Shipped at 4 °C. Store at -20 °C for up to one year.**Swiss Prot:** [Q5TZJ5](#)**GeneID:** [647060](#)**Gene Symbol:** SPATA31A1**Directions for use:**

1. Transfect with 100 nM siRNA 48 to 72 hours prior to cell lysis.
2. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube.
3. Resuspend the siRNA oligos to an appropriate concentration with DEPC water.

Each vial is suitable for 250 transfections in a 24 well plate (20 pmol for each well).**Quality Control:** Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.

**Note:** This product is for research use only.